Briefly, this study demonstrates that both HIF1α and HIF2α, as genes upstream of Sox2, regulate the

malignant progression of glioma through dedifferentiation. Therefore, we unexpectedly identified both

HIF1α and HIF2α as critical targets in glioma. In addition, Sox2, another factor, was studied in this article
and found to be an ideal target for glioma treatment because it was highly expressed in glioma but
expressed at low levels in normal tissues. Based on our results, we conclude that the dedifferentiation
process is induced under hypoxic conditions via regulation by the HIF1α/HIF2α-Sox2 pathway, which
provides new ideal targets for glioma treatment.